Paul Underwood
Cardiovascular Disease · Scottsdale, AZNPI 1588665681
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $252,500 of the $258,743 with a category attached, or 97.6%. Boston Scientific accounts for 94.5% of it on its own, with 12 other manufacturers making up the rest. 2025 is the largest year on record at $134,042, more than ten times the $498 reported in 2019. Among cardiovascular disease clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 70 payments — averaging $3696.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$245K
- Alnylam Pharmaceuticals Inc.$11K
- Novo Nordisk$1K
- AstraZeneca$442
- Medtronic$365
- Amgen$280
- plus $866 from 7 others
What the payments were for
- Consulting fees$252,50098%
- Travel & lodging$2,4261%
- Food & beverage$3,8171%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 21 | $244,641 |
| Alnylam Pharmaceuticals Inc. | 16 | $10,921 |
| Novo Nordisk | 15 | $1,229 |
| AstraZeneca | 4 | $442 |
| Medtronic(2 entities) | 4 | $365 |
| Amgen | 2 | $280 |
| Teva Pharmaceuticals USA, Inc. | 2 | $225 |
| Abbott | 1 | $166 |
| Inspire Medical Systems, Inc. | 1 | $145 |
| Sanofi-aventis U.S. LLC | 1 | $108 |
| RARE Disease Therapeutics, Inc. | 1 | $97 |
| Asahi Intecc USA, Inc. | 1 | $92 |
| Penumbra, Inc. | 1 | $34 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CLINICAL TRIAL PRODUCT$122,625
- Repatha$280
- Wegovy$183
- Inspire$145
- SYNCHROMEDII$142
- INTELLIS ADAPTIVESTIM$138
- AUSTEDO$118
- Enhertu$115
- FARXIGA$111
- TOUJEO$108
- AJOVY$107
How this compares
$258,743 in reported general payments places this provider in the 95th percentile of 423 cardiovascular disease providers in Arizona.
Other cardiovascular disease in Scottsdale
- Krishnaswami VijayaraghavanScottsdale$927K
- Robert BurkeScottsdale$207K
- David RizikScottsdale$128K
- Martin CerdaScottsdale$66K
- Pattara RattanawongScottsdale$43K
- Mayank SardanaScottsdale$36K
- Ashish GuptaPhoenix$1.1M
- Rajkumar SugumaranPhoenix$957K
- Steven MottlTucson$340K
- Omar WaniFlagstaff$244K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.